Peter Hodson YM BioSciences YM-T DON'T BUY Feb 19, 2007

The only biotech stock that he owns. Accumulates on weakness. Had 2 trials on their cancer drug without getting approval, but this isn't a concern. Statistically difficult to get approval in 2 tries. Is expecting a successful end point. Have a fantastic pipeline of other drugs as well.

Tesmilifene is the 1st compound they’ll have pivotal phase 3 results on and the stock should move up strongly. Behind that, Nimotuzumab is a great compound that has some interesting phase 2 trials. Great risk/reward.

In spite of its setback, he still likes. Risks/reward at this point is not bad. Speculative.

Recently suffered when phase 3 testing failed. Has cash in the bank, has a long runway (cash on a burn rate). Have 2 products in phase 3, one of which is approved in India and China. Great opportunities. Way undervalued.